Target Information

Target General Infomation
Target ID
T57718
Former ID
TTDI02217
Target Name
Melanoma-associated antigenC2
Gene Name
MAGEC2
Synonyms
CT10; Cancer/testis antigen 10; Hepatocellular carcinomaassociated antigen 587; MAGEC2 antigen; MAGEE1 antigen; MAGEC2
Target Type
Clinical Trial
Disease Non-small cell lung cancer [ICD10: C33-C34]
Function
Proposed to enhance ubiquitin ligase activity of RING- type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.
BioChemical Class
Melanoma associated antigen family
UniProt ID
Q9UBF1
Sequence
MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSS
LILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQK
GEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPV
ILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIK
GNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFL
WGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASE
SLSVMSSNVSFSE
Drugs and Mode of Action
Drug(s) CV-9201 Drug Info Phase 1/2 Non-small cell lung cancer [522696]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
References
Ref 522696ClinicalTrials.gov (NCT00923312) Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health.
Ref 550441National Cancer Institute Drug Dictionary (drug id 648549).